Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BAMLANIVIMAB\ETESEVIMAB Cause Erythema? 44 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Erythema have been filed in association with BAMLANIVIMAB\ETESEVIMAB. This represents 5.3% of all adverse event reports for BAMLANIVIMAB\ETESEVIMAB.

44
Reports of Erythema with BAMLANIVIMAB\ETESEVIMAB
5.3%
of all BAMLANIVIMAB\ETESEVIMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Erythema From BAMLANIVIMAB\ETESEVIMAB?

Of the 44 reports, 2 (4.5%) required hospitalization, and 6 (13.6%) were considered life-threatening.

Is Erythema Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BAMLANIVIMAB\ETESEVIMAB. However, 44 reports have been filed with the FAERS database.

What Other Side Effects Does BAMLANIVIMAB\ETESEVIMAB Cause?

Infusion related reaction (309) Dyspnoea (172) Flushing (130) Chest discomfort (103) Back pain (83) Nausea (79) Incorrect dose administered (75) Transcription medication error (67) Chest pain (66) Dizziness (59)

What Other Drugs Cause Erythema?

ADAPALENE (38,965) AVOBENZONE\OCTISALATE\OCTOCRYLENE (30,872) DUPILUMAB (10,877) ADALIMUMAB (4,829) ETANERCEPT (3,733) AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE (3,462) INFLIXIMAB (2,919) METHOTREXATE (2,835) SECUKINUMAB (2,824) RITUXIMAB (2,460)

Which BAMLANIVIMAB\ETESEVIMAB Alternatives Have Lower Erythema Risk?

BAMLANIVIMAB\ETESEVIMAB vs BARACLUDE BAMLANIVIMAB\ETESEVIMAB vs BARICITINIB BAMLANIVIMAB\ETESEVIMAB vs BARIUM BAMLANIVIMAB\ETESEVIMAB vs BARNIDIPINE BAMLANIVIMAB\ETESEVIMAB vs BASILIXIMAB

Related Pages

BAMLANIVIMAB\ETESEVIMAB Full Profile All Erythema Reports All Drugs Causing Erythema BAMLANIVIMAB\ETESEVIMAB Demographics